WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s
Exploring Serration-Enhanced BTK Angioplasty: Investigators share case-based perspectives and trial experiences with the Serranator PTA Serration Balloon Catheter, now FDA-cleared for use below-the-knee. With Michael
Cagent Vascular (Wayne, PA), a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its Serranator® PTA Serration
Cagent Vascular (Wayne, PA), a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces the initiation of the PRELUDE-BTK Study. The purpose
– Walsh’s Commercial Expertise will Benefit Cagent’s Efforts to Develop Serranator Market – Cagent Vascular®, a developer of next generation angioplasty balloons using proprietary serration
WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular®, a developer of next generation angioplasty balloons using proprietary serration technology, announced the completion of $11.87 million in Series B funding.
Serranator® has achieved regulatory approvals from both FDA and European Medicines Agency, paving way for successful commercialization WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular, a developer of next-generation
WAYNE, Pa. –(BUSINESS WIRE)– Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, including the FDA 510(k) cleared Serranator® Alto PTA
WAYNE, Pa.–(BUSINESS WIRE)—Cagent Vascular, a developer of next generation technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its lead product,